Abstract
Breast cancer is the neoplasia with the highest incidence rate among women in the world. Estrogens are indicated as the main risk factor for this pathology. SERMs (selective estrogen receptor modulators) and aromatase inhibitors (AI) and tyrosine kinase (TK) inhibitors are the established antineoplastic agents for breast cancer therapy because of their antiestrogenic properties. However, …